Drug intelligence / Profile preview

sulfadoxine-pyrimethamine + amodiaquine + ferrous fumarate

Development stage: Preclinical
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

A combination medication containing sulfadoxine-pyrimethamine, amodiaquine, and ferrous fumarate. The sulfadoxine-pyrimethamine and amodiaquine components are used for malaria treatment and prevention, particularly in areas with chloroquine resistance. Sulfadoxine-pyrimethamine works by inhibiting two different steps in the biosynthesis of tetrahydrofolate in the malaria parasite, while amodiaquine has antimalarial properties. Ferrous fumarate is an iron supplement that may be included to address potential anemia in malaria patients.

Targets

DHPS (Dihydropteroate synthase)HemeDHFR-TS (Bifunctional dihydrofolate reductase-thymidylate synthase)

Beyond the preview

Go deeper on sulfadoxine-pyrimethamine + amodiaquine + ferrous fumarate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sulfadoxine-pyrimethamine + amodiaquine + ferrous fumarate.

Explore the full profile